Defining human pathways of drug metabolism in vivo through the development of a multiple humanized mouse model

Drug Metabolism and Disposition

Volumn 43, Issue 11, 2015, Pages 1679-1690

  Scheer, Nico ^a,d   Kapelyukh, Yury ^c   Rode, Anja ^a   Oswald, Stefan ^b   Busch, Diana ^b   McLaughlin, Lesley A ^c   Lin, De ^c   Henderson, Colin J ^c   Wolf, C Roland ^c  

^a Taconic Farms Inc   (United States)

^b UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUFURALOL; CYTOCHROME P450; CYTOCHROME P450 2B; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DICLOFENAC; ERYTHROMYCIN; KETOCONAZOLE; MIDAZOLAM; PHENOBARBITAL; PREGNANE X RECEPTOR; RIFAMPICIN; SELECTIVE ANDROGEN RECEPTOR MODULATOR; TRIAZOLAM; CYP3A PROTEIN, HUMAN; CYTOCHROME P450 3A; DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALYSIS; CONTROLLED STUDY; CYP2C GENE; CYP2D GENE; CYP3A GENE; DRUG DISTRIBUTION; DRUG INHIBITION; DRUG METABOLISM; ENZYME METABOLISM; ENZYME REGULATION; ENZYME SPECIFICITY; FEMALE; GENE; HOMOZYGOSITY; HYDROXYLATION; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; POLYPHARMACY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; ANIMAL; ANIMAL MODEL; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; CYTOCHROME P-450 CYP3A; HUMANS; MALE; MICE; MICE, TRANSGENIC; MICROSOMES, LIVER; MODELS, ANIMAL; PHARMACEUTICAL PREPARATIONS; SIGNAL TRANSDUCTION;

EID: 84946202761     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.065656     Document Type: Article

References (59)

1. Backman JT, Olkkola KT, and Neuvonen PJ (1996) Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 59:7-13.
2. Berry LM and Zhao Z (2008) An examination of IC50 and IC50-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes. Drug Metab Lett 2:51-59.
3. Cheung C and Gonzalez FJ (2008) Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. J Pharmacol Exp Ther 327: 288-299.
4. Cheung C, Yu AM, Chen C.S., Krausz KW, Byrd LG, Feigenbaum L, Edwards R.J., Waxman DJ, and Gonzalez FJ (2006) Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice. J Pharmacol Exp Ther 316:1328-1334.
5. Corchero J, Granvil CP, Akiyama T.E., Hayhurst GP, Pimprale S, Feigenbaum L, Idle J.R., and Gonzalez FJ (2001) The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Mol Pharmacol 60: 1260-1267.
6. Daneshmend TK, Warnock DW, Turner A, and Roberts CJ (1981) Pharmacokinetics of ketoconazole in normal subjects. J Antimicrob Chemother 8:299-304.
7. DeLozier TC, Tsao CC, Coulter S.J., Foley J., Bradbury JA, Zeldin DC, and Goldstein JA (2004) CYP2C44, a new murine CYP2C that metabolizes arachidonic acid to unique stereospecific products. J Pharmacol Exp Ther 310:845-854.
8. Felmlee MA, Lon HK, Gonzalez F.J., and Yu AM (2008) Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice. Drug Metab Dispos 36: 435-441.
9. Fitch WL, Tran T, Young M., Liu L, and Chen Y (2009) Revisiting the metabolism of ketoconazole using accurate mass. Drug Metab Lett 3:191-198.
10. Forrester LM, Henderson CJ, Glancey M.J., Back DJ, Park BK, Ball SE, Kitteringham N.R., McLaren AW, Miles JS, and Skett P, et al. (1992) Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J 281:359-368.
11. Gebhardt R, Hengstler JG, Müller D, Glöckner R, Buenning P., Laube B, Schmelzer E, Ullrich M., Utesch D, and Hewitt N, et al. (2003) New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab Rev 35:145-213.
12. Granvil CP, Yu AM, Elizondo G, Akiyama T.E., Cheung C., Feigenbaum L, Krausz KW, and Gonzalez FJ (2003) Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam. Drug Metab Dispos 31:548-558.
13. Gröer C., Busch D, Patrzyk M., Beyer K, Busemann A, Heidecke C.D., Drozdzik M., Siegmund W, and Oswald S (2014) Absolute protein quantification of clinically relevant cytochrome P450 enzymes and UDP-glucuronosyltransferases by mass spectrometry-based targeted proteomics. J Pharm Biomed Anal 100:393-401.
14. Guengerich FP (2008) Cytochrome p450 and chemical toxicology. Chem Res Toxicol 21:70-83.
15. Guest EJ, Rowland-Yeo K, Rostami-Hodjegan A, Tucker GT, Houston J.B., and Galetin A (2011) Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models. Br J Clin Pharmacol 71:72-87.
16. Hasegawa M, Kapelyukh Y, Tahara H., Seibler J, Rode A, Krueger S., Lee DN, Wolf CR, and Scheer N (2011) Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse line. Mol Pharmacol 80:518-528.
17. Kakkar T, Boxenbaum H, and Mayersohn M (1999) Estimation of Ki in a competitive enzymeinhibition model: comparisons among three methods of data analysis. Drug Metab Dispos 27: 756-762.
18. Kakkar T, Pak Y, and Mayersohn M (2000) Evaluation of a minimal experimental design for determination of enzyme kinetic parameters and inhibition mechanism. J Pharmacol Exp Ther 293:861-869.
19. Kazuki Y, Kobayashi K, Aueviriyavit S., Oshima T, Kuroiwa Y, Tsukazaki Y., Senda N, Kawakami H, Ohtsuki S., and Abe S, et al. (2013) Trans-chromosomic mice containing a human CYP3A cluster for prediction of xenobiotic metabolism in humans. Hum Mol Genet 22:578-592.
20. Krippendorff BF, Neuhaus R, Lienau P., Reichel A, and Huisinga W (2009) Mechanism-based inhibition: deriving K(I) and k(inact) directly from time-dependent IC(50) values. J Biomol Screen 14:913-923.
21. Lazarou J, Pomeranz BH, and Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279:1200-1205.
22. Lichti-Kaiser K and Staudinger JL (2008) The traditional Chinese herbal remedy tian Xian activates pregnane X receptor and induces CYP3A gene expression in hepatocytes. Drug Metab Dispos 36:1538-1545.
23. Liu X, Hu L, Ge G., Yang B, Ning J, Sun S., Yang L, Pors K, and Gu J (2014) Quantitative analysis of cytochrome P450 isoforms in human liver microsomes by the combination of proteomics and chemical probe-based assay. Proteomics 14:1943-1951.
24. Ma X, Cheung C, Krausz K.W., Shah YM, Wang T, Idle JR, and Gonzalez FJ (2008) A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4. Drug Metab Dispos 36:2506-2512.
25. Ma X, Shah Y, Cheung C., Guo GL, Feigenbaum L, Krausz KW, Idle J.R., and Gonzalez FJ (2007) The PREgnane X receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cytochromes P450 3A. Drug Metab Dispos 35:194-200.
26. Martignoni M, Groothuis GM, and de Kanter R (2006) Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875-894.
27. Maurer TS, Tabrizi-Fard MA, and Fung HL (2000) Impact of mechanism-based enzyme inactivation on inhibitor potency: implications for rational drug discovery. J Pharm Sci 89:1404-1414.
28. Mayhew BS, Jones DR, and Hall SD (2000) An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 28: 1031-1037.
29. McConn DJ, 2nd, Lin YS, Allen K, Kunze KL, and Thummel KE (2004) Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Drug Metab Dispos 32:1083-1091.
30. Nelson DR, Zeldin DC, Hoffman S.M., Maltais LJ, Wain HM, and Nebert DW (2004) Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14:1-18.
31. Ohtsuki S, Schaefer O, Kawakami H., Inoue T, Liehner S, Saito A., Ishiguro N, Kishimoto W, Ludwig-Schwellinger E, and Ebner T, et al. (2012) Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos 40:83-92.
32. Omiecinski CJ, Vanden Heuvel JP, Perdew GH, and Peters JM (2011) Xenobiotic metabolism, disposition, and regulation by receptors: from biochemical phenomenon to predictors of major toxicities. Toxicol Sci 120 (Suppl 1):S49-S75.
33. Perloff MD, von Moltke LL, Court MH, Kotegawa T, Shader RI, and Greenblatt DJ (2000) Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. J Pharmacol Exp Ther 292:618-628.
34. Pirmohamed M, James S, Meakin S., Green C, Scott AK, Walley T.J., Farrar K., Park BK, and Breckenridge AM (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329:15-19.
35. Pritchard MP, Glancey MJ, Blake J.A., Gilham DE, Burchell B, Wolf CR, and Friedberg T (1998) Functional co-expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli. Pharmacogenetics 8:33-42.
36. Pritchard MP, Ossetian R, Li D.N., Henderson CJ, Burchell B, Wolf CR, and Friedberg T (1997) A general strategy for the expression of recombinant human cytochrome P450s in Escherichia coli using bacterial signal peptides: expression of CYP3A4, CYP2A6, and CYP2E1. Arch Biochem Biophys 345:342-354.
37. Reagan-Shaw S., Nihal M, and Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22:659-661.
38. Rostami-Hodjegan A (2012) Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther 92:50-61.
39. Scheer N, Kapelyukh Y, Chatham L., Rode A, Buechel S, and Wolf CR (2012a) Generation and characterization of novel cytochrome P450 Cyp2c gene cluster knockout and CYP2C9 humanized mouse lines. Mol Pharmacol 82:1022-1029.
40. Scheer N, Kapelyukh Y, McEwan J., Beuger V, Stanley LA, Rode A, and Wolf CR (2012b) Modeling human cytochrome P450 2D6 metabolism and drug-drug interaction by a novel panel of knockout and humanized mouse lines. Mol Pharmacol 81:63-72.
41. Scheer N, McLaughlin LA, Rode A, Macleod A.K., Henderson CJ, and Wolf CR (2014) Deletion of 30 murine cytochrome p450 genes results in viable mice with compromised drug metabolism. Drug Metab Dispos 42:1022-1030.
42. Scheer N and Roland Wolf C (2013) Xenobiotic receptor humanized mice and their utility. Drug Metab Rev 45:110-121.
43. Scheer N, Ross J, Kapelyukh Y., Rode A, and Wolf CR (2010) In vivo responses of the human and murine pregnane X receptor to dexamethasone in mice. Drug Metab Dispos 38: 1046-1053.
44. Scheer N, Ross J, Rode A., Zevnik B, Niehaves S, Faust N., and Wolf CR (2008) A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response. J Clin Invest 118:3228-3239.
45. Scheer N and Wolf CR (2014) Genetically humanized mouse models of drug metabolizing enzymes and transporters and their applications. Xenobiotica 44:96-108.
46. Shen HW, Jiang XL, Gonzalez F.J., and Yu AM (2011) Humanized transgenic mouse models for drug metabolism and pharmacokinetic research. Curr Drug Metab 12:997-1006.
47. Stanley LA, Horsburgh BC, Ross J, Scheer N., and Wolf CR (2006) PXR and CAR: nuclear receptors which play a pivotal role in drug disposition and chemical toxicity. Drug Metab Rev 38:515-597.
48. Tang H, Hussain A, Leal M., Mayersohn M, and Fluhler E (2007) Interspecies prediction of human drug clearance based on scaling data from one or two animal species. Drug Metab Dispos 35:1886-1893.
49. van der Bol JM, Mathijssen RH, Creemers G.J., Planting AS, Loos WJ, Wiemer EA, Friberg L.E., Verweij J., Sparreboom A, and de Jong FA (2010) A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin Cancer Res 16:736-742.
50. van Herwaarden A.E., Smit JW, Sparidans R.W., Wagenaar E., van der Kruijssen CM, Schellens JH, Beijnen JH, and Schinkel AH (2005) Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4. Drug Metab Dispos 33:892-895.
51. van Herwaarden A.E., Wagenaar E, van der Kruijssen CM, van Waterschoot RA, Smit JW, Song JY, van der Valk MA, van Tellingen O, van der Hoorn JW, and Rosing H, et al. (2007) Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 117:3583-3592.
52. van Waterschoot R.A., van Herwaarden AE, Lagas JS, Sparidans RW, Wagenaar E, van der Kruijssen CM, Goldstein JA, Zeldin DC, Beijnen JH, and Schinkel AH (2008) Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. Mol Pharmacol 73:1029-1036.
53. Walsky RL, Obach RS, Hyland R, Kang P., Zhou S, West M, Geoghegan K.F., Helal CJ, Walker GS, and Goosen TC, et al. (2012) Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs. Drug Metab Dispos 40:1686-1697.
54. Watanabe M, Kumai T, Matsumoto N., Tanaka M, Suzuki S, Satoh T., and Kobayashi S (2004) Expression of CYP3A4 mRNA is correlated with CYP3A4 protein level and metabolic activity in human liver. J Pharmacol Sci 94:459-462.
55. Williams JA, Hyland R, Jones B.C., Smith DA, Hurst S, Goosen TC, Peterkin V, Koup J.R., and Ball SE (2004) Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-1208.
56. Xie W, Barwick JL, Downes M, Blumberg B., Simon CM, Nelson MC, Neuschwander-Tetri BA, Brunt EM, Guzelian P.S., and Evans RM (2000) Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 406:435-439.
57. Yu AM, Fukamachi K, Krausz K.W., Cheung C., and Gonzalez FJ (2005) Potential role for human cytochrome P450 3A4 in estradiol homeostasis. Endocrinology 146:2911-2919.
58. Zhang J, Huang W, Chua S.S., Wei P., and Moore DD (2002) Modulation of acetaminopheninduced hepatotoxicity by the xenobiotic receptor CAR. Science 298:422-424.
59. Zhou J, Zhai Y, Mu Y., Gong H, Uppal H, Toma D., Ren S, Evans RM, and Xie W (2006) A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway. J Biol Chem 281:15013-15020.